---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-027707"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:38:51.126069+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q4 2024 net loss $194.6M, cash $2.3B; Phase 3 PDAC enrollment target 2025

## Summary
- Q4 net loss $194.6M vs $161.5M YoY; full year net loss $600.1M vs $436.4M.
- Cash and securities $2.3B at Dec 31, 2024, up from $1.9B; $823M net raised in Dec 2024 public offering.
- 2025 GAAP net loss guidance $840M-$900M; cash runway expected into H2 2027.
- Expects to complete enrollment in Phase 3 RASolute 302 (PDAC) in 2025 for data readout in 2026; Phase 3 RASolve 301 (NSCLC) now activating sites.
- Plans to initiate two additional registrational trials for daraxonrasib in earlier-line PDAC in H2 2025.

## SEC filing metadata
- accession: 0000950170-25-027707
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000095017025027707/0000950170-25-027707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000095017025027707/rvmd-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-027707
- JSON: https://secwatch.observer/filing/0000950170-25-027707.json
- Plain text: https://secwatch.observer/filing/0000950170-25-027707.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.